CTRI/2020/09/027629已完成3 期
A Phase III, Comparative, Double Blind, Randomized, Multi-centric study to compare the Efficacy, Safety and Immunogenicity of Sun�s Ranibizumab with Reference Biologic in Patients with Neovascular Age-related Macular degeneration (wet AMD)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 161
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Ambulatory patients of either gender with ââ?°Â¥ 50 years of age at the time of screening and who are capable of understanding and giving written informed consent.
- •2)Active primary or recurrent subfoveal lesions with classic or occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
- •(Please note: Only one eye will be considered for study. If both eyes are eligible, the one with the better visual acuity will be selected for treatment unless, based on medical reasons, the investigator deemed the other eye to be more appropriate for treatment. If both eyes have similar visual acuity and similar medical reasons, then right eye will be selected)
- •3)Best corrected visual acuity, using Early Treatment of Diabetic Retinopathy Study (ETDRS) chart, of 20/40 to 20/320 (Snellen equivalent) in the study eye before pupil dilation.
- •4)Women of childbearing potential must have a negative urine pregnancy test prior to study entry and agree to use highly effective methods of contraception to prevent pregnancy from study entry till the last dose of the study medication (such contraception may include hormonal birthcontrol e.g., combined estrogen and progestogen containing [oral, intravaginal, or transdermal] or progesterone only [oral, injectable, or implantable] hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone releasing system OR bilateral tubal occlusion, vasectomized partner, or sexual abstinence)
- •[Note: Women with childbearing potential are defined as: those who are not (1) surgically sterile (bilateral oophorectomy, hysterectomy, or bilateral tubal ligation) or (2) post-menopausal
- •Post-menopausal woman will be defined as: Women not using hormonal replacement therapy and have had at least 12 continuous months of natural (spontaneous) amenorrhea and be greater than 45 years of age]
排除标准
- •A.Prior/Concomitant treatment
- •1)Prior treatment with verteporfin, external-beam radiation therapy, or transpupillary thermotherapy (TTT), intravitreal drug delivery (steroids or device implantation), anti-VEGF drugs, sub foveal laser photocoagulation, vitrectomy surgery, submacular surgery or other surgical intervene for AMD or any other therapy for AMD in the study eye
- •2)Intraocular surgery (including cataract surgery) in the study eye within 2 months prior to randomization.
- •3)Past or Concurrent use of systemic anti-VEGF agents
- •4)Previous participation in a clinical trial (for either eye) involving anti-angiogenic drugs
- •5)Previous participation in any studies of investigational drugs within 1 month preceding randomization (excluding vitamins and minerals) or planning to participate any other study during the course of this study.
- •6)Treatment with verteporfin photodynamic therapy in the non-study eye less than 7 days preceding day 1.
- •7)Laser Photocoagulation (juxtafoveal and extrafoveal) in study eye within 1 month prior to randomization.
- •B.Ocular conditions in study eye
- •8)Subfoveal fibrosis or atrophy
- •9)Sub retinal hemorrhage that involved the center of the fovea, if the size of the hemorrhage was > 50% of the total lesion area
- •10)Retinal pigment epithelial tear that involved the macula
- •11)Any concurrent intraocular condition in the study eye (e.g., cataract, diabetic retinopathy, the refractive error more than -8 diopters of myopia etc.) that, in the opinion of the investigator, either
- •Ã¯Æ?Ë?Required medical or surgical intervention during study period to prevent or treat visual loss that may have resulted from that condition, or
- •Ã¯Æ?Ë?If allowed to progress untreated, could likely have contributed to loss of at least 2 Snellen equivalent lines of best corrected visual acuity over the study period
- •12)Patients with current vitreous hemorrhage or history of (1) rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) (2) glaucoma filtering surgery (3) corneal transplant
- •13)Aphakia or absence of the posterior capsule
- •14)Active intraocular inflammation (grade trace or above)
- •15)Uncontrolled glaucoma in the study eye (defined as intraocular pressure [IOP] ââ?°Â¥ 30 mmHg despite treatment with anti-glaucoma medication)
- •16)Patients with Polypoidal choroidal vasculopathy (PCV) disease at the time of Screening
- •C.Concurrent ocular conditions in either eyes
- •17)Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis
- •18)History of idiopathic or autoimmune-associated uveitis
- •19)CNV in either eye due to other causes, such as ocular histoplasmosis, trauma or pathologic myopia or CNV lesion not likely to respond to Ranibizumab.
- •D.Concurrent Systemic Conditions
- •20)Current signs or symptoms of significant, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, any immunodeficiency and/ or immunosuppressive disease or active systemic infection, cerebral disease that renders the patient incapable of participating in the study.
- •21)Patients with controlled and uncontrolled Diabetes
- •E.Other Criteria:
- •22)Known hypersensitivity to Ranibizumab or any of the components of study medication
研究者
相似试验
进行中（未招募）
不适用
A study of intravenous iron isomaltoside 1000 (Monofer®) compared to placebo in subjects with iron deficiency anaemia who are Intolerant or unresponsive to oral iron therapySubjects with iron deficiency anaemia (IDA) caused by different aetiologies such as abnormal uterine bleeding, gastrointestinal diseases (e.g. inflammatory bowel disease), cancer, preoperative anaemia (e.g. orthopaedic surgery), and other conditions leading to IDA and with a documented history of intolerance or unresponsiveness to oral iron therapy.MedDRA version: 17.1Level: PTClassification code 10022972Term: Iron deficiency anaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-001518-25-DEPharmacosmos A/S200
进行中（未招募）
1 期
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageEUCTR2013-003535-30-GBGlaxoSmithKline Biologicals1,220
进行中（未招募）
1 期
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageEUCTR2013-003535-30-DEGlaxoSmithKline Biologicals1,220
进行中（未招募）
1 期
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageVaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life).MedDRA version: 18.1Level: PTClassification code 10069613Term: Varicella immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10069628Term: Varicella immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10063315Term: Varicella zoster virus DNA test positiveSystem Organ Class: 100000004848MedDRA version: 18.0Level: LLTClassification code 10046983Term: Varicella zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: PTClassification code 10046980Term: VaricellaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.0Level: LLTClassification code 10050331Term: Varicella-like rashSystem Organ Class: 100000004858MedDRA version: 18.0Level: LLTClassification code 10063144Term: Varicella zoster virus serology positiveSystem Organ Class: 100000004848EUCTR2013-003535-30-EEGlaxoSmithKline Biologicals1,220
未知
3 期
A Study to Observe the Efficacy and Safety of Febuxostat in Subjects with Gout and HyperuricemiaGout, HyperuricemiaJPRN-jRCT2080222060Astellas Pharma China, Inc.594